【广东会GDH基因检测】肝细胞癌的分子分类

靶向药一般多少钱排名

研究高效抑制肿瘤转移的方法与药物看到《Dig Liver Dis》在. 2010 Jul;42 Suppl 3:S235-41.发表了一篇题目为《肝细胞癌的分子分类》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Jessica Zucman-Rossi等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

肝细胞癌（HCC）是贼常见的源自肝细胞恶变的肿瘤。众所周知，癌症是一种基因组疾病，与其他类型的实体瘤一样，在肝癌发生过程中积累了大量的遗传和表观遗传改变。使用综合基因组工具的贼新发展使得能够识别人类 HCC 中的分子多样性。因此，已经使用不同的基因解码基因检测的研究方法描述了几种分子分类，并取得了重要进展，特别是在转录组、遗传、染色体、miRNA 和甲基化分析方面。总的来说，所有这些分子分类都是相关的，确定的肿瘤亚组的主要决定因素之一是在癌基因和肿瘤抑制基因中发现的基因突变。然而，对 HCC 分子分类的全面了解需要使用基因组和通路分析进行额外的综合研究。贼后，考虑到患者的地理和遗传多样性，对 HCC 的分子分类进行改进，这对于有效设计即将到来的个性化临床治疗至关重要。

肿瘤发生与反复转移国际数据库描述：

Hepatocellular carcinoma (HCC) is the most frequent tumour derived from the malignant transformation of hepatocytes. It is well established that cancer is a disease of the genome and, as in other types of solid tumours, a large number of genetic and epigenetic alterations are accumulated during the hepatocarcinogenesis process. Recent developments using comprehensive genomic tools have enabled the identification of the molecular diversity in human HCC. Consequently, several molecular classifications have been described using different approaches and important progress has been made particularly with the transcriptomic, genetic, chromosomal, miRNA and methylation profiling. On the whole, all these molecular classifications are related and one of the major determinants of the identified subgroups of tumours are gene mutations found in oncogenes and tumour suppressors. However, the full understanding of the HCC molecular classification requires additional comprehensive studies using both genomic and pathway analyses. Finally, a refinement of the molecular classification of HCC, taking into account the geographical and genetic diversity of the patients, will be essential for an efficient design of the forthcoming personalized clinical treatments.